10-Q: Merit Medical Q2 Sales Up, Profit Dips Amid Acquisitions

Merit Medical Systems reports increased net sales for Q2 2025 driven by acquisitions and international demand, but net income and EPS declined due to higher operating expenses and tax rates.

Summary

• Net sales for the three months ended June 30, 2025, increased by 13.2% to $382.5 million, up from $338.0 million in the prior year period.
• Net sales for the six months ended June 30, 2025, increased by 11.5% to $737.8 million, up from $661.5 million in the prior year period.
• Gross profit as a percentage of sales increased to 48.2% for the three-month period and 48.3% for the six-month period ended June 30, 2025, compared to 47.7% and 47.3% respectively in 2024.
• Net income for the three months ended June 30, 2025, was $32.6 million ($0.54 per diluted share), down from $35.7 million ($0.61 per diluted share) in the prior year.
• Net income for the six months ended June 30, 2025, was $62.7 million ($1.03 per diluted share), down from $64.0 million ($1.09 per diluted share) in the prior year.
• Selling, General and Administrative (SG&A) expenses increased by 19.6% to $113.1 million for the three-month period and 16.7% to $220.6 million for the six-month period.
• Research and Development (R&D) expenses increased by 20.3% to $24.4 million for the three-month period and 12.2% to $46.8 million for the six-month period.
• The effective income tax rate increased to 24.9% for the three-month period and 22.9% for the six-month period ended June 30, 2025, compared to 22.1% and 20.2% respectively in 2024.
• Cash and cash equivalents decreased to $341.8 million as of June 30, 2025, from $376.7 million as of December 31, 2024.
• Total assets increased to $2.59 billion as of June 30, 2025, from $2.42 billion as of December 31, 2024.
• Long-term debt remained stable at $731.8 million as of June 30, 2025, primarily consisting of $747.5 million in convertible notes due 2029.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While net income and EPS declined, this was largely due to increased operating expenses associated with significant acquisitions that are driving strong top-line revenue growth. The company's strategic expansion through M&A, coupled with improved gross margins and robust sales in key segments and geographies, indicates underlying business strength. However, the ongoing SEC inquiry and general macroeconomic risks temper the overall positive outlook.

Positives

• Net sales increased significantly by 13.2% for the quarter and 11.5% for the six-month period, demonstrating strong top-line growth.
• Gross profit percentage improved to 48.2% for the quarter and 48.3% for the six-month period, indicating favorable product mix and operational efficiency.
• Cardiovascular segment sales grew by 11.0% for the quarter and 9.6% for the six-month period, driven by increased demand for peripheral intervention and cardiac intervention products.
• Endoscopy segment sales showed substantial growth, increasing by 81.0% for the quarter and 72.6% for the six-month period, largely due to the EsophyX Z+ device acquisition.
• U.S. sales increased by 16.7% for the quarter and 15.7% for the six-month period, indicating strong domestic market performance.
• International sales grew by 8.4% for the quarter and 5.8% for the six-month period, with notable increases in ROW (14.0% for Q2) and EMEA (16.5% for Q2) regions.
• The company maintains a strong liquidity position with $343.9 million in cash and cash equivalents and approximately $697 million in available borrowing capacity under its credit agreement.
• Acquisitions of Biolife (May 2025), Cook's lead management business (November 2024), and EGS (July 2024) are contributing to revenue growth and expanding the product portfolio.

Negatives

• Net income decreased by 8.5% for the three-month period and 2.0% for the six-month period, despite higher sales, indicating pressure on profitability.
• Diluted earnings per common share decreased to $0.54 for the quarter (from $0.61) and $1.03 for the six-month period (from $1.09).
• Operating expenses, particularly SG&A and R&D, increased significantly, outpacing sales growth and impacting net income.
• Interest income decreased due to reduced cash and cash equivalent balances, contributing to higher 'other expense net'.
• The effective income tax rate increased, further impacting net income.
• Cash and cash equivalents decreased by $34.9 million during the six-month period, primarily due to significant cash outflows for investing activities, including acquisitions.
• Inventory balances increased by $11.7 million during the six-month period, partly due to building bridge inventory for production line transfers and safety stock for vendor supply delays.

Risks

• Ongoing SEC inquiry regarding business activities of the China subsidiary, with an unpredictable scope, timing, significance, or outcome, potentially leading to materially adverse effects.
• Changes in economic and geopolitical conditions, including inflation, global credit market instability, and uncertainty regarding central bank monetary policy.
• Trade policy changes, including increased tariffs on imports (e.g., from Mexico, Ireland, China), which could significantly increase manufacturing costs and prompt retaliatory actions.
• Disruptions or delays to the global supply chain, potentially impacting production costs and product availability.
• Potential inability to successfully manage growth through acquisitions, including challenges in effectively integrating acquired operations or products and achieving anticipated financial results.
• Fluctuations in interest or foreign currency exchange rates and inflation, which can adversely affect financial results.
• Cybersecurity events posing risks to company IT systems and data.
• Difficulties relating to development, testing, and regulatory approval of products.
• Modification or limitation of, or policies and procedures associated with, governmental or private insurance reimbursement policies.
• Litigation and other judicial proceedings, including the Thompson Dispute, which could result in significant claims or settlements.
• Failure to comply with U.S. and foreign laws and regulations, including Anti-Corruption Laws and Trade Control Laws.
• Restrictions on liquidity or business operations resulting from debt agreements.
• Infringement of company technology or assertions that company technology infringes on others' rights.
• Product recalls and product liability claims.
• Potential for significant adverse changes in governing regulations.
• Changes in tax laws and regulations, including the OECD Pillar Two global minimum tax rules and the 'One Big Beautiful Bill Act' in the U.S., which could increase the effective tax rate.
• Termination of relationships with suppliers or their failure to perform.
• Development of new products and technology by competitors that could render existing or future products obsolete.
• Market acceptance of new products.
• Labor shortages and increases in labor costs, particularly in Mexico.
• Leadership transition with the appointment of a new President and CEO, which may be disruptive to the business and relationships with stakeholders.

Future Outlook

The company anticipates continued impact from recent developments and trends, including demand in the U.S. and favorable international sales. It expects its existing cash balances, future cash flows from operations, and long-term debt borrowings to be adequate for current and planned future operations for the next twelve months and the foreseeable future. The company is evaluating the impact of new accounting standards (ASU 2023-09 and ASU 2024-03) and tax legislation (OECD Pillar Two and OBBBA), but does not anticipate a material impact to its fiscal 2025 consolidated results from the global minimum tax or the OBBBA.

Management Comments

• Our revenue results during the three-month period ended June 30, 2025 were driven primarily by demand in the U.S. and favorable international sales trends, particularly in our Rest of World (ROW) and Europe, the Middle East and Africa (EMEA) regions.
• We continue to closely monitor the evolving trade policy environment which presents a mix of impacts, including, among other impacts, the potential for increased production costs and higher pricing to our customers, any of which could negatively affect our business, results of operations and financial condition.
• We currently believe that our existing cash balances, anticipated future cash flows from operations and borrowings under our long-term debt agreements will be adequate to fund our current and currently planned future operations for the next twelve months and the foreseeable future.
• In the event we pursue and complete significant transactions or acquisitions in the future, additional funds may be required to meet our strategic needs, which may require us to raise additional funds in the debt or equity markets.

Industry Context

The medical device industry is characterized by continuous innovation, regulatory complexities, and global market dynamics. Merit Medical's focus on interventional, diagnostic, and therapeutic procedures, particularly in cardiovascular and endoscopy, positions it in high-growth segments. The company's recent acquisitions (Biolife, Cook's lead management, EGS) reflect a strategy of expanding its product portfolio and market reach, aligning with a broader industry trend of consolidation and specialization to capture market share and leverage synergies. However, the industry also faces challenges from global economic conditions, trade policy shifts, and increasing regulatory scrutiny, as evidenced by the SEC inquiry into the company's China operations.

Comparison to Industry Standards

• The company's gross profit percentage of 48.2% (Q2 2025) is generally in line with or slightly below the average for specialized medical device manufacturers, which can range from 45% to 70% depending on product complexity and market position. For example, companies like Boston Scientific or Medtronic often report gross margins in the 60-70% range for their higher-value interventional products, suggesting Merit may have a more diversified or lower-margin product mix, or higher cost of goods sold.
• The decline in net income and EPS despite strong revenue growth indicates that operating expenses (SG&A, R&D) are growing faster than sales. This trend is not uncommon for companies undergoing significant integration of acquired businesses, as seen with the Biolife, Cook, and EGS acquisitions, which typically incur substantial integration and labor-related costs. Larger, more mature industry players often demonstrate better operating leverage.
• The company's R&D spending at 6.4% of sales (Q2 2025) is competitive within the medical device sector, where R&D investment is crucial for innovation and maintaining market relevance. This level of investment is comparable to many mid-cap medical technology firms focused on product development.
• The increase in inventory due to 'bridge inventory for production line transfers and increases in safety stock due to vendor supply delays' highlights ongoing supply chain challenges that are prevalent across the global manufacturing sector, including medical devices, post-pandemic. This is a common issue affecting many industry participants.

Management Changes

Corporate Governance

Legal Proceedings

• An ongoing SEC inquiry commenced in January 2022, seeking information related to the business activities of the company's subsidiary in China, including interactions with hospitals and healthcare officials. The company is cooperating and investigating the matter, but the scope, timing, significance, or outcome, and associated loss, are currently unpredictable and could be materially adverse.
• The company is involved in various claims and litigation matters in the ordinary course of business, including product liability, intellectual property, contract disputes, employment, and governmental inquiries. While management believes no other matters are individually or in aggregate materially adverse, outcomes could differ from estimates.

Related Party Transactions

• No officer or director of the Acquired Companies or any Person owning 5% or more of the Shares (or any of such Person's immediate family members or Affiliates or associates) is a party to any Contract with or binding upon the Acquired Companies or any of its assets, rights or properties or has any interest in any assets, rights, or properties owned or used by the Acquired Companies or has engaged in any transaction with respect to any of the foregoing within the twelve (12) month period prior to the date of this Agreement.

Stakeholder Impact

• **Shareholders:** Potential for long-term value creation through strategic acquisitions and revenue growth, but short-term profitability decline and ongoing SEC inquiry may create volatility and uncertainty.
• **Employees:** Headcount additions due to acquisitions, continued competitive compensation and benefits, and a leadership transition with a new CEO. Employees of acquired companies will be eligible for 401(k) participation and service credit. Severance payments are outlined for employees terminated post-Merger Effective Time.
• **Customers:** Expanded product portfolio through acquisitions (e.g., StatSeal, WoundSeal, EsophyX Z+, Cook's lead management) offers broader solutions. Potential for increased pricing due to tariffs is a risk.
• **Suppliers:** Potential for disruptions or delays in the global supply chain and increased production costs due to trade policies and inflation.
• **Creditors:** The company maintains compliance with financial covenants and has substantial available borrowing capacity, indicating a stable credit profile despite increased debt from convertible notes.

Next Steps

• Continue integration of Biolife, Cook's lead management business, and EGS acquisitions.
• Monitor and manage the ongoing SEC inquiry regarding China subsidiary business activities.
• Evaluate the impact of new accounting standards (ASU 2023-09 and ASU 2024-03) on financial statement disclosures.
• Assess the impact of the OECD Pillar Two global minimum tax rules and the 'One Big Beautiful Bill Act' on the effective tax rate.
• Proceed with the leadership transition, with Martha Aronson assuming the CEO role on October 3, 2025.
• Continue investments in property and equipment, with anticipated capital expenditures of $90 million to $100 million in 2025, including a new distribution facility in South Jordan, Utah.

Key Dates

Recommendation

While Merit Medical Systems demonstrates strong revenue growth driven by strategic acquisitions and favorable market demand, the decline in net income and diluted EPS raises concerns about profitability and operating leverage. Increased operating expenses and a higher effective tax rate are impacting the bottom line. The ongoing SEC inquiry into the China subsidiary introduces significant regulatory uncertainty and potential financial liabilities. The upcoming CEO transition, while planned, also adds a layer of execution risk. Given the mixed financial performance, the strategic growth initiatives, and the notable risks, a 'hold' recommendation is appropriate, suggesting investors monitor the company's ability to integrate acquisitions profitably, resolve the SEC inquiry, and manage the leadership transition effectively before making further investment decisions.

Keywords

Medical Devices, Interventional Procedures, Cardiology, Radiology, Oncology, Endoscopy, Healthcare, SEC Filing, 10-Q, Financial Results, Acquisitions, Biolife, Cook Medical, EsophyX Z+, Earnings, Revenue, Profitability, Risk Factors, Corporate Governance, Leadership Change